Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/karger/a-retrospective-study-of-immunotherapy-treatment-with-uro-vaxom-om-89-4XrqSqMhSH
- Publisher
- Karger
- Copyright
- © 2020 The Author(s) Published by S. Karger AG, Basel
- ISSN
- 1661-7649
- eISSN
- 1661-7657
- DOI
- 10.1159/000499248
- Publisher site
- See Article on Publisher Site
Abstract
Objectives: To present our experience with the long-term preventive effect of immunotherapy with Uro-Vaxom® on recurrent urinary tract infections (UTI) in adult patients. Materials and Methods: Retrospective analysis of 79 patients with recurrent UTI treated with Uro-Vaxom. Recurrent UTIs were defined as ≥ 2 infections in 6 months or ≥ 3 in 12 months. Patients received a 6 mg Uro-Vaxom capsule daily for 90 days followed by discontinuation for 3 months and then administration for the first 10 days of subsequent months 7, 8 and 9 as a ‘booster' regime. The primary outcome measure was the number of UTIs encountered in the 12 months pre-treatment compared to 12 months post-treatment. Results: There was a significant decrease in the mean number of UTIs in the year following initiation of Uro-Vaxom® compared to the year preceding administration 3.14 versus 1.53 (p < 0.05) respectively. Conclusion: Uro-Vaxom represents a safe and effective treatment option for prophylaxis of recurrent UTIs. In the UK, Uro-Vaxom is currently unlicensed. This study adds to a growing body of evidence in favor of non-antibiotic immune-prophylaxis for recurrent UTI.
Journal
Current Urology – Karger
Published: Jan 1, 2020
Keywords: Uro-Vaxom; Immunotherapy;